Is Your Crohn's Treatment Losing Its Power? Spotting and Tackling Infliximab Resistance
"A deep dive into infliximab resistance in Crohn's disease: what the latest research reveals about predicting and overcoming loss of response."
Crohn's disease (CD), a chronic inflammatory bowel disease (IBD), presents lifelong challenges for those affected. Characterized by diverse symptoms and impacting quality of life, CD management often involves powerful medications like infliximab (IFX). Infliximab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), has revolutionized CD treatment, offering relief from inflammation and improving patient outcomes.
However, the effectiveness of infliximab can diminish over time. This phenomenon, known as loss of response (LOR), occurs when patients who initially respond well to the drug start experiencing a return of their symptoms. Understanding why LOR happens and how to predict it is crucial for optimizing treatment strategies and maintaining long-term remission.
A recent systematic review and meta-analysis has shed light on potential predictors of LOR to infliximab therapy in adults with CD. This article breaks down the study's findings, offering insights into who is most at risk and what steps can be taken to combat infliximab resistance.
Current Burden of Resistance
Infliximab resistance is a clinically important concern for some people with Crohn’s disease, but its frequency and impact can vary by definition, treatment history, and follow-up period. Loss of response may require closer monitoring and treatment reassessment. Patients should discuss new or returning symptoms with their healthcare team rather than assuming that treatment failure has a single cause.
Standard Monitoring and Its Limits
Infliximab is established as an effective treatment for inducing and maintaining clinical remission and mucosal healing in Crohn’s disease, although the cited studies report primary non-response in approximately 9%–40% of patients. Research has examined clinical and molecular models for predicting non-response, including models using Crohn’s disease-related microarray datasets collected from the GEO database. In patients with loss of response, one controlled trial found that an algorithm based on infliximab and anti-infliximab antibody levels achieved clinical equivalence to dose escalation while offering a cost benefit. These findings support therapeutic drug monitoring as a useful approach, while also showing that prediction models and treatment algorithms remain imperfect.
How Infliximab Became Established
Infliximab’s role in Crohn’s disease developed through its recognition as an effective biologic treatment for inflammatory bowel disease. Over time, clinical practice has expanded beyond simply administering the drug to evaluating response, loss of response, and possible immunogenicity. The historical picture is therefore one of increasing personalization, although the available material does not establish a detailed timeline of individual milestones.
What Predicts Infliximab Resistance in Crohn's Disease?
Researchers conducted a comprehensive search of English-language articles published between 1990 and March 2017, analyzing data from multiple studies to identify factors associated with LOR to infliximab. The meta-analysis consolidated data from 26 studies, encompassing 3,187 patients, to determine the rate of LOR and identify potential predictors.
- Perianal Lesions: Patients with perianal lesions (sores or inflammation around the anus) were more likely to experience LOR.
- Colon Involvement: CD affecting the colon was associated with a higher risk of infliximab resistance.
- Younger Age at CD Onset: Individuals who developed CD at a younger age were also more prone to LOR.
Current Evidence and New Delivery Options
Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor-alpha, which is present at high levels in the blood serum, mucosa, and stool of people with Crohn’s disease. The treatment has been used since the late 1990s, and subcutaneous infliximab has been available for Crohn’s disease since 2020. A 2024 study observed subcutaneous infliximab for 52 weeks in refractory Crohn’s disease patients who had failed at least two previous treatment lines. Research reported in 2025 also examined treatment persistence after infliximab dose adjustment, with secondary loss of response described as potentially related to low serum drug levels and immunogenicity.
Why Treatment Failure Is Difficult to Interpret
A return of Crohn’s disease symptoms does not by itself establish that infliximab has permanently lost its effectiveness. Treatment response can be difficult to evaluate because clinical symptoms, inflammatory activity, drug exposure, and immune responses may not move together. For that reason, claims about resistance should be interpreted cautiously and assessed through individualized clinical evaluation.
Comparing Treatment Strategies
The available material does not provide a direct head-to-head comparison of infliximab with alternative biologics or treatment strategies. It does indicate that both intravenous and subcutaneous infliximab are being studied or used in Crohn’s disease. Meaningful comparison therefore requires attention to response, persistence, administration route, and the patient’s prior treatment history rather than relying on one outcome alone.
Taking Control of Your Crohn's Journey
While the study highlights potential risk factors for infliximab resistance, it's important to remember that every patient's experience with Crohn's disease is unique. If you're concerned about losing response to infliximab, talk to your doctor. They can assess your individual risk factors, monitor your symptoms closely, and adjust your treatment plan as needed. With proactive management and open communication, you can overcome challenges and maintain a good quality of life with Crohn's disease.
Putting Resistance in Context
Infliximab resistance is best understood as a problem requiring reassessment rather than as a single, uniform event. The available evidence points toward combining clinical assessment with information about drug levels, anti-drug antibodies, and disease activity when response declines. Prediction tools may help identify risk, but they should complement rather than replace individualized medical decisions.
Toward Predictive and Flexible Care
Future research is examining how infliximab is used in routine practice, including real-world trends in subcutaneous and intravenous infliximab from 2021 to 2024 in the Crohn’s Colitis Cure Data Insights Program. Another emerging direction is machine-learning prediction of infliximab response using clinical characteristics and longitudinal laboratory trends. Together, these projects suggest movement toward more data-informed treatment selection and monitoring, although their practical value will depend on validation and implementation in clinical care.
The Consequences of Stopping Therapy
Long-term infliximab management involves balancing treatment burden against the risk of disease recurrence. A study of patients with Crohn’s disease in clinical, biochemical, and endoscopic remission reported that discontinuing long-term infliximab carries a considerable risk of relapse. The broader treatment context therefore includes decisions about persistence and discontinuation, not only whether a patient currently has symptoms.
Living With Uncertain Response
For people living with Crohn’s disease, a possible loss of infliximab response can create uncertainty about symptoms, monitoring, and next treatment steps. The available material does not quantify these personal effects, so their severity and form should not be generalized across patients. Shared discussions with clinicians remain important when symptoms change or treatment decisions are being reconsidered.